I
Isabelle Mancini
Researcher at Université libre de Bruxelles
Publications - 13
Citations - 1727
Isabelle Mancini is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Delirium & Palliative care. The author has an hindex of 9, co-authored 13 publications receiving 1663 citations. Previous affiliations of Isabelle Mancini include Grey Nuns Community Hospital.
Papers
More filters
Journal ArticleDOI
Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study.
Peter G. Lawlor,Bruno Gagnon,Isabelle Mancini,Jose Pereira,John Hanson,Maria E. Suarez-Almazor,Eduardo Bruera +6 more
TL;DR: Delirium precipitated by opioids and other psychoactive medications and dehydration is frequently reversible with change of opioid or dose reduction, discontinuation of unnecessary psychoactive medication, or hydration, respectively, and patients with delirium had poorer survival rates than controls.
Occurrence, Causes, and Outcome of Delirium in Patients With Advanced Cancer
Peter G. Lawlor,Bruno Gagnon,Isabelle Mancini,Jose Pereira,John Hanson,Maria E. Suarez-Almazor,Eduardo Bruera +6 more
TL;DR: In this paper, the authors found that patients with delirium had poorer survival rates than controls (P.001) when compared to patients with nonreversibility, and psychoactive medications, predominantly opioids, were associated with reversibility.
Journal ArticleDOI
Constipation in advanced cancer patients
Isabelle Mancini,Eduardo Bruera +1 more
TL;DR: In this paper, the authors reviewed the pathophysiology and causes of constipation and the effects of opioids on the gastrointestinal tract, and proposed an approach for its assessment and management, including general interventions, such as the availability of comfort and privacy or the elimination of medical factors that may contribute to constipation, and therapeutic interventions including oral or rectal laxatives and the use of prokinetic drugs and naloxone.
Journal ArticleDOI
Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
TL;DR: Nonstandard, intensive treatment with i.v. ibandronate seems to have a marked analgesic effect in patients with opioid-resistant bone pain from metastatic bone disease, and improved QOL, patient functioning, and performance status.
Journal ArticleDOI
Bisphosphonates for cancer patients: Why, how, and when?
TL;DR: Because BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration have to be different from those used for classic antineoplastic drugs, and they should be stopped when metastatic bone disease is progressing.